Table 1.
Main characteristics of the training and validation cohorts.
| Cohorts | Training | Validation | FisherTestPv |
|---|---|---|---|
| Characteristic | 133 | 132 | |
| Sex | 1.0000 | ||
| Male | 90 | 89 | |
| Female | 43 | 43 | |
| Age_at_diag | 65 (45–84) | 61 [32, 84] | |
| Unknown | 9 | 1 | |
| Immunotherapy PD1/PDL1 | 0.3463 | ||
| PD1 based | 132 | 116 | |
| PDL1 based | 1 | 16 | |
| Immunotherapy monotherapy/combo | 1.0000 | ||
| Monotherapy | 129 | 129 | |
| Combo therapy | 4 | 3 | |
| Immunotherapy monotherapy/combo | 0.0000 | ||
| Nivolumab-based | 99 | 113 | |
| Pembrolizumab-based | 33 | 3 | |
| Others | 1 | 16 | |
| Response | 0.0814 | ||
| SD | 28 | 46 | |
| PD | 76 | 63 | |
| PR | 18 | 18 | |
| CR | 9 | 4 | |
| Unknown | 2 | 1 | |
| Pfs_event | 112 | 118 | |
| Pfs_time | 4.5 (0–41) | 3 [0–67] | |
| Unknown | 1 | ||
| OS_event | 96 | 105 | 1.0000 |
| Unknown | 2 | 3 | |
| OS_time | 12.5 (0–41) | 11 [0–95] | |
| Unknown | 2 | 7 |
133 NSCLC patients were included in a training cohort. An independent cohort of 132 NSCLC patients from a different care centre was used as validation. Nivolumab was the most frequently prescribed treatment, followed by pembrolizumab. The majority of patients received monotherapy as standard of care.